SwingTrade Member Forum

[Rawnoc]

REPR more -- "We believe the Freedom60 continues to find a solid following in the subcutaneous immune globulin market and with the introduction of a new 20% IgG drug released early this year, this market is expected to continue to increase both domestically and internationally. We continue to experience an increase in sales and cash during nine months ended November 30, 2010 and with these increases and the capital we currently have, we will continue to meet or exceed the company's financial needs for the next twelve months."